ClinicalTrials.gg
CompletedNCT02399345Updated Dec 12, 2016Results posted

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

A Phase 3 interventional study of ombitasvir/paritaprevir/ritonavir, dasabuvir and sofosbuvir (SOF) in Chronic Hepatitis C Virus (HCV Infection Genotype 1), sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-12-12.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing ombitasvir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. ombitasvir · Hepatitis C, Chronic.

Enrollment
19th of 19
10 · median 148
Started
2015
with 6 others
Phase 3
10 of 19
none open now
Registered
12th of 19
by date
Lead sponsor
8 of 19
AbbVie

Among the 19 studies testing ombitasvir in Hepatitis C, Chronic, this one is the 19th largest by enrollment, is one of 7 that started in 2015, is one of 10 in phase 3, and was the 12th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 19 studies testing ombitasvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ombitasvir

ombitasvir: first FDA approval 2014 (VIEKIRA PAK (COPACKAGED)), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing ombitasvir in Hepatitis C, Chronic as a file.
02

Study summary

This open-label study will evaluate the safety and efficacy of co-formulated ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with sofosbuvir with or without ribavirin administered for either 4 or 6 weeks in treatment naive adults with chronic HCV-genotype 1 infection without cirrhosis

03

Conditions studied

  • Chronic Hepatitis C Virus (HCV Infection Genotype 1)

Browse trials for

Keywords

  • Treatment naive
  • Hepatitis C Genotype 1
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female at least 18 years of age at time of screening
  2. Chronic virus (HCV) infection prior to study enrollment
  3. Screening laboratory results from the central clinical laboratory indicating HCV genotype 1 infection only
  4. Absence of cirrhosis and advanced bridging fibrosis

Exclusion criteria

Exclusion Criteria:

  1. Positive test result for surface antigen (HbsAg) or (HIV) positive immunoassay
  2. abnormalities or co-morbidities, other than infection, that make the subject an unsuitable candidate for this study or treatment with Ribavirin (RBV) in the opinion of the investigator
  3. Any current or past clinical evidence of cirrhosis such as ascites or esophageal varices, or prior showing cirrhosis or advanced bridging fibrosis, e.g., a Metavir score > 2 or an Ishak score > 3
  4. Use of medications for ombitasvir/paritaprevir/ritonavir, dasabuvir, sofosbuvir, or ribavirin (RBV; for those that receive RBV), within 2 weeks or 10 half-lives whichever is longer, prior to study drug administration
  5. Current enrolment in another clinical study, previous enrolment in this study, or previous use of any or commercially available anti-HCV agents
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV

    Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir, dasabuvir · Drug: sofosbuvir (SOF) · Drug: ribavirin (RBV)

Interventions

  • Drugombitasvir/paritaprevir/ritonavir, dasabuvir

    Drug pages: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir

    tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

    Also known as: Viekira PAK, ombitasvir also known as ABT-267, paritaprevir also known as ABT-450, dasabuvir also known as ABT-333

  • tablet

  • tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment

    The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.

    Time frame: 12 weeks after the last actual dose of study drug

Secondary outcomes

  1. Percentage of Subjects With On-treatment Virologic Failure

    Virologic failure during treatment was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements \> 1 log10 IU/mL above nadir) during treatment; or failure to suppress during treatment (defined as all values of HCV RNA ≥ LLOQ during treatment).

    Time frame: 6 weeks

  2. Percentage of Subjects With Post-treatment Relapse

    Percentage of subjects with HCV RNA less than the lower limit of quantification at the end of treatment with confirmed HCV RNA greater than or equal to the lower limit of quantification through 12 weeks post treatment

    Time frame: Up to 12 weeks after last actual dose of active study drug

07

Results

Posted Dec 12, 2016

Participant flow

A total 10 participants were enrolled in the first arm (ombitasvir/paritaprevir/r, dasabuvir, and SOF plus RBV for 6 weeks); based on inadequate efficacy in the first arm, subsequent arms (4 weeks of treatment; with or without RBV) were not enrolled per protocol.

Participant flow — Overall Study
MilestoneOmbitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV
Started10
Completed10
Not completed0

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment

The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment
percentage of participantsOmbitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV
Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment80
SecondaryPercentage of Subjects With On-treatment Virologic Failure

Virologic failure during treatment was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements \> 1 log10 IU/mL above nadir) during treatment; or failure to suppress during treatment (defined as all values of HCV RNA ≥ LLOQ during treatment).

Time frame:
6 weeks
Reported as:
Number · percentage of participants
Percentage of Subjects With On-treatment Virologic Failure
percentage of participantsOmbitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV
Percentage of Subjects With On-treatment Virologic Failure0
SecondaryPercentage of Subjects With Post-treatment Relapse

Percentage of subjects with HCV RNA less than the lower limit of quantification at the end of treatment with confirmed HCV RNA greater than or equal to the lower limit of quantification through 12 weeks post treatment

Time frame:
Up to 12 weeks after last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of Subjects With Post-treatment Relapse
percentage of participantsOmbitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV
Percentage of Subjects With Post-treatment Relapse20

Adverse events

Collected over Treatment-emergent Adverse Events (TEAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 10 weeks); Serious Adverse Events (SAEs) were collected from the time informed consent was obtained (up to 15 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV—1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventOmbitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV
ANXIETYPsychiatric disorders1/10
PHYSICAL ASSAULTSocial circumstances1/10
Most frequent other events
Showing 10 of 46
Most frequent other events
EventOmbitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV
FATIGUEGeneral disorders5/10
INSOMNIAPsychiatric disorders5/10
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/10
HEADACHENervous system disorders3/10
CONSTIPATIONGastrointestinal disorders2/10
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders2/10
NAUSEAGastrointestinal disorders2/10
ARTHRALGIAMusculoskeletal and connective tissue disorders2/10
IRRITABILITYPsychiatric disorders2/10
DYSPNOEA EXERTIONALRespiratory, thoracic and mediastinal disorders2/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV
Mean46.4 ± 11.30
Sex: Female, Male
Sex: Female, Male(Participants)Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF Plus RBV
Female4
Male6
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2015
First posted
Mar 26, 2015
Start
Mar 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Dec 12, 2016
Last update
Dec 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02399345
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 26, 2015
Start date
Mar 2015
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Dec 12, 2016
Last update
Dec 12, 2016

Study contacts

Eric Cohen, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Sofosbuvir · Ribavirin

Start the discussion